CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
54.32
+1.50 (2.84%)
At close: Aug 22, 2025, 4:00 PM
54.75
+0.43 (0.79%)
After-hours: Aug 22, 2025, 7:59 PM EDT
CRISPR Therapeutics AG Stock Forecast
Stock Price Forecast
The 15 analysts that cover CRISPR Therapeutics AG stock have a consensus rating of "Buy" and an average price target of $72.27, which forecasts a 33.04% increase in the stock price over the next year. The lowest target is $32 and the highest is $120.
Price Target: $72.27 (+33.04%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CRISPR Therapeutics AG stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 6 | 6 | 6 | 6 | 6 |
| Buy | 4 | 4 | 3 | 3 | 3 | 3 |
| Hold | 9 | 8 | 6 | 7 | 6 | 6 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 19 | 16 | 17 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $65 → $80 | Strong Buy | Maintains | $65 → $80 | +47.28% | Aug 7, 2025 |
| Barclays | Barclays | Hold Maintains $42 → $56 | Hold | Maintains | $42 → $56 | +3.09% | Aug 6, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $82 | Strong Buy | Maintains | $82 | +50.96% | Aug 5, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $38 → $42 | Hold | Maintains | $38 → $42 | -22.68% | Aug 5, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $79 → $78 | Strong Buy | Maintains | $79 → $78 | +43.59% | Jul 22, 2025 |
Financial Forecast
Revenue This Year
47.88M
from 37.31M
Increased by 28.31%
Revenue Next Year
176.21M
from 47.88M
Increased by 268.05%
EPS This Year
-5.53
from -4.34
EPS Next Year
-4.56
from -5.53
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 150.2M | 1.6B | 2.4B | ||
| Avg | 47.9M | 176.2M | 410.8M | ||
| Low | n/a | n/a | 37.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 302.4% | 3,145.8% | 1,250.7% | ||
| Avg | 28.3% | 268.0% | 133.1% | ||
| Low | - | - | -78.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -4.00 | 2.68 | 4.94 | ||
| Avg | -5.53 | -4.56 | -3.55 | ||
| Low | -6.58 | -6.68 | -7.60 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.